Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential

Jun Shi, Kazuma Ikeda, Yoshinobu Maeda, Katsuji Shinagawa, Aiji Ohtsuka, Hajime Yamamura, Mitsune Tanimoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells (PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in vitro generated myeloid dendritic cells (MDCs). In this article, we investigated whether the expression of CD123 on monocyte-derived MDCs was related to their function, especially to tumor-inhibiting potential. MDCs were induced from cord blood CD14+ monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days, and then CD123+ cells were isolated by positive immunomagnetic cell selection. We observed that CD123+ cells lost monocyte CD14 expression, acquired immature myeloid dendritic cell phenotype and morphology. They exerted more significant endocytosis and less antigen-presenting function than CD123-MDCs which are often referred to as typical MDCs. Meanwhile, CD123+ MDCs exhibited more significant tumor-inhibiting activity toward hematological tumor cell lines of U937 and Jurkat even at a low effector:target ratio. CD123+ MDCs expressed higher level of cytoplasmic TNF-α-related apoptosis-inducing ligand (TRAIL), but no detectable surface TRAIL and very little soluble TRAIL. Pretreatment with recombinant human TRAIL receptor 2:Fc fusion protein significantly reduced the tumor-inhibiting effect of CD123+ MDCs, but not of CD123- MDCs. Overall, our data demonstrated that CD123+ MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalCancer Letters
Volume270
Issue number1
DOIs
Publication statusPublished - Oct 18 2008

Fingerprint

Myeloid Cells
Dendritic Cells
TNF-Related Apoptosis-Inducing Ligand
Monocytes
Neoplasms
TNF-Related Apoptosis-Inducing Ligand Receptors
Interleukin-7
Granulocyte-Macrophage Colony-Stimulating Factor
Endocytosis
Tumor Cell Line
Fetal Blood
Interleukin-4
Phenotype
Antigens

Keywords

  • CD123
  • Myeloid dendritic cells
  • TRAIL
  • Tumor-inhibiting activity

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. / Shi, Jun; Ikeda, Kazuma; Maeda, Yoshinobu; Shinagawa, Katsuji; Ohtsuka, Aiji; Yamamura, Hajime; Tanimoto, Mitsune.

In: Cancer Letters, Vol. 270, No. 1, 18.10.2008, p. 19-29.

Research output: Contribution to journalArticle

Shi, Jun ; Ikeda, Kazuma ; Maeda, Yoshinobu ; Shinagawa, Katsuji ; Ohtsuka, Aiji ; Yamamura, Hajime ; Tanimoto, Mitsune. / Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. In: Cancer Letters. 2008 ; Vol. 270, No. 1. pp. 19-29.
@article{6aace45d669141c987e0f2793463c246,
title = "Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential",
abstract = "CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells (PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in vitro generated myeloid dendritic cells (MDCs). In this article, we investigated whether the expression of CD123 on monocyte-derived MDCs was related to their function, especially to tumor-inhibiting potential. MDCs were induced from cord blood CD14+ monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days, and then CD123+ cells were isolated by positive immunomagnetic cell selection. We observed that CD123+ cells lost monocyte CD14 expression, acquired immature myeloid dendritic cell phenotype and morphology. They exerted more significant endocytosis and less antigen-presenting function than CD123-MDCs which are often referred to as typical MDCs. Meanwhile, CD123+ MDCs exhibited more significant tumor-inhibiting activity toward hematological tumor cell lines of U937 and Jurkat even at a low effector:target ratio. CD123+ MDCs expressed higher level of cytoplasmic TNF-α-related apoptosis-inducing ligand (TRAIL), but no detectable surface TRAIL and very little soluble TRAIL. Pretreatment with recombinant human TRAIL receptor 2:Fc fusion protein significantly reduced the tumor-inhibiting effect of CD123+ MDCs, but not of CD123- MDCs. Overall, our data demonstrated that CD123+ MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL.",
keywords = "CD123, Myeloid dendritic cells, TRAIL, Tumor-inhibiting activity",
author = "Jun Shi and Kazuma Ikeda and Yoshinobu Maeda and Katsuji Shinagawa and Aiji Ohtsuka and Hajime Yamamura and Mitsune Tanimoto",
year = "2008",
month = "10",
day = "18",
doi = "10.1016/j.canlet.2008.04.048",
language = "English",
volume = "270",
pages = "19--29",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential

AU - Shi, Jun

AU - Ikeda, Kazuma

AU - Maeda, Yoshinobu

AU - Shinagawa, Katsuji

AU - Ohtsuka, Aiji

AU - Yamamura, Hajime

AU - Tanimoto, Mitsune

PY - 2008/10/18

Y1 - 2008/10/18

N2 - CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells (PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in vitro generated myeloid dendritic cells (MDCs). In this article, we investigated whether the expression of CD123 on monocyte-derived MDCs was related to their function, especially to tumor-inhibiting potential. MDCs were induced from cord blood CD14+ monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days, and then CD123+ cells were isolated by positive immunomagnetic cell selection. We observed that CD123+ cells lost monocyte CD14 expression, acquired immature myeloid dendritic cell phenotype and morphology. They exerted more significant endocytosis and less antigen-presenting function than CD123-MDCs which are often referred to as typical MDCs. Meanwhile, CD123+ MDCs exhibited more significant tumor-inhibiting activity toward hematological tumor cell lines of U937 and Jurkat even at a low effector:target ratio. CD123+ MDCs expressed higher level of cytoplasmic TNF-α-related apoptosis-inducing ligand (TRAIL), but no detectable surface TRAIL and very little soluble TRAIL. Pretreatment with recombinant human TRAIL receptor 2:Fc fusion protein significantly reduced the tumor-inhibiting effect of CD123+ MDCs, but not of CD123- MDCs. Overall, our data demonstrated that CD123+ MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL.

AB - CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells (PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in vitro generated myeloid dendritic cells (MDCs). In this article, we investigated whether the expression of CD123 on monocyte-derived MDCs was related to their function, especially to tumor-inhibiting potential. MDCs were induced from cord blood CD14+ monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 7 days, and then CD123+ cells were isolated by positive immunomagnetic cell selection. We observed that CD123+ cells lost monocyte CD14 expression, acquired immature myeloid dendritic cell phenotype and morphology. They exerted more significant endocytosis and less antigen-presenting function than CD123-MDCs which are often referred to as typical MDCs. Meanwhile, CD123+ MDCs exhibited more significant tumor-inhibiting activity toward hematological tumor cell lines of U937 and Jurkat even at a low effector:target ratio. CD123+ MDCs expressed higher level of cytoplasmic TNF-α-related apoptosis-inducing ligand (TRAIL), but no detectable surface TRAIL and very little soluble TRAIL. Pretreatment with recombinant human TRAIL receptor 2:Fc fusion protein significantly reduced the tumor-inhibiting effect of CD123+ MDCs, but not of CD123- MDCs. Overall, our data demonstrated that CD123+ MDCs were an early-stage immature DC subset, with a significant tumor-inhibiting activity partially via involvement of enhanced cytoplasmic TRAIL.

KW - CD123

KW - Myeloid dendritic cells

KW - TRAIL

KW - Tumor-inhibiting activity

UR - http://www.scopus.com/inward/record.url?scp=50649089386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649089386&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.04.048

DO - 10.1016/j.canlet.2008.04.048

M3 - Article

VL - 270

SP - 19

EP - 29

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -